Sun Pharma’s MM-II: The Six-Month Solution That Could Transform Knee Osteoarthritis Forever

Unknown Apr 02, 2026 1,600 Views

Sun Pharma and Israel's Moebius Medical have announced impressive new results from their worldwide Phase 2b MM-II clinical trial of a new non-opioid intra-articular injection for pain of knee osteoarthritis. The study, reported at EULAR 2024, demonstrates a single 3mL intra-articular dose of...

Highlights:

Sustained Efficacy: Weeks 12 through 26, a higher percentage of patients treated with MM-II had at least a 50% decrease in pain associated with knee osteoarthritis compared with placebo and used less rescue medication.

Favorable Safety Profile: MM-II had a safety profile similar to placebo, with minimal rates of treatment-emergent adverse reactions and equal rates of injection site reactions.

Novel Mechanism: MM-II has a proprietary suspension of large, empty, multilamellar liposomes aimed at lowering joint friction and wear, providing an alternative to opioids for osteoarthritis pain relief.

Regulatory Momentum: MM-II received Fast Track designation from the U.S. FDA, speeding up its development and approval based on its ability to fill a significant unmet need in osteoarthritis therapy.

Next Steps: Sun Pharma and Moebius Medical are now planning Phase 3 confirmatory trials and seeking a CE Mark for MM-II in the European Union, signaling global ambitions for this innovative therapy.

Expert Endorsement: Abhay Gandhi, CEO of Sun Pharma North America, highlighted the significant unmet need for osteoarthritis therapies, emphasizing MM-II’s potential to transform pain management for millions suffering from joint pain worldwide.

These innovations place MM-II as a highly promising, safe, and long-lasting alternative to current osteoarthritis remedies, poised to redefine the treatment landscape for individuals with knee pain.

Sources: Economic Times, Sun Pharma Press Release, Pharmaceutical Commerce

Stay Ahead – Explore Now! Nifty 50 and Nifty Bank Surge in Strong Pre-Open Trade